oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-4-67-77oncotomsk-1143Research ArticleОБЗОРЫREVIEWSПРИМЕНЕНИЕ ПЭТ/КТ В ДИАГНОСТИКЕ, СТАДИРОВАНИИ И МОНИТОРИНГЕ КОЛОРЕКТАЛЬНОГО РАКАTHE VALUE OF PET/CT IN THE DIAGNOSIS, STADING AND MONITORING OF COLORECTAL CANCERЧерновВ. И.ChernovV. I.

доктор медицинских наук, профессор, заместитель директора по научной работе и инновационной деятельности, руководитель отделения радионуклидной диагностики,

г. Томск, 634009, пер. Кооперативный, 5

MD, DSc, Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department,

5, Kooperativny Street, 634009-Tomsk

chernov@tnimc.ruГончароваН. М.GoncharovaN. M.

младший научный сотрудник отделения химиотерапии,

г. Томск, 634009, пер. Кооперативный, 5

MD, Junior Researcher, Chemotherapy Department,

5, Kooperativny Street, 634009-Tomsk

ГольдбергВ. Е.GoldbergV. E.

доктор медицинских наук, заведующий отделением химиотерапии,

г. Томск, 634009, пер. Кооперативный, 5

MD, DSc, Professor, Head of Chemotherapy Department,

5, Kooperativny Street, 634009-Tomsk

ДудниковаЕ. А.DudnikovaE. A.

младший научный сотрудник отделения химиотерапии,

г. Томск, 634009, пер. Кооперативный, 5

MD, Junior Researcher, Chemotherapy Department,

5, Kooperativny Street, 634009-Tomsk

ЗельчанР. В.ZelchanR. V.

кандидат медицинских наук, врач отделения радионуклидной диагностики, 

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Radiologist, Nuclear Medicine Department,

5, Kooperativny Street, 634009-Tomsk

МедведеваА. А.MedvedevaA. A.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, 

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Senior Researcher, Nuclear Medicine Department,

5, Kooperativny Street, 634009-Tomsk

СинилкинИ. Г.SinilkinI. G.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, 

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Senior Researcher, Nuclear Medicine Department,

5, Kooperativny Street, 634009-Tomsk

БрагинаО. Д.BraginaO. D.

кандидат медицинских наук, младший научный сотрудник отделения радионуклидной диагностики,  

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Junior Researcher, Nuclear Medicine Department,

5, Kooperativny Street, 634009-Tomsk

АвгустиновичА. В.AvgustinovichA. V.

кандидат медицинских наук, научный сотрудник отделения абдоминальной онкологии, 

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Researcher, Abdominal Department,

5, Kooperativny Street, 634009-Tomsk

ГольдбергА. В.GoldbergA. V.

младший научный сотрудник отделения лучевой диагностики,

г. Томск, 634009, пер. Кооперативный, 5

MD, Junior Researcher, Department of Radiation Diagnostics,

5, Kooperativny Street, 634009-Tomsk

ЕрмоленкоР. В.ErmolenkoR. V.

аспирант отделения лучевой диагностики,

г. Томск, 634009, пер. Кооперативный, 5

MD. Postgraduate, Radiology Department,

5, Kooperativny Street, 634009-Tomsk

ПоповаН. О.PopovaN. O.

кандидат медицинских наук, старший научный сотрудник отделения химиотерапии,

 г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Senior Researcher, Chemotherapy Department,

5, Kooperativny Street, 634009-Tomsk

СимолинаЕ. И.SimolinaE. I.

кандидат медицинских наук, научный сотрудник отделения химиотерапии,

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Researcher, Department of Chemotherapy,

5, Kooperativny Street, 634009-Tomsk

ВысоцкаяВ. В.VysotskayaV. V.

кандидат медицинских наук, научный сотрудник отделения химиотерапии,

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Researcher, Chemotherapy Department,

5, Kooperativny Street, 634009-Tomsk

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of ScienceRussian Federation2019010920191846777Copyright © Чернов В.И., Гончарова Н.М., Гольдберг В.Е., Дудникова Е.А., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Августинович А.В., Гольдберг А.В., Ермоленко Р.В., Попова Н.О., Симолина Е.И., Высоцкая В.В., 20192019Чернов В.И., Гончарова Н.М., Гольдберг В.Е., Дудникова Е.А., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Августинович А.В., Гольдберг А.В., Ермоленко Р.В., Попова Н.О., Симолина Е.И., Высоцкая В.В.Chernov V.I., Goncharova N.M., Goldberg V.E., Dudnikova E.A., Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Avgustinovich A.V., Goldberg A.V., Ermolenko R.V., Popova N.O., Simolina E.I., Vysotskaya V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1143

Цель исследования – представить современные данные об эффективности применения позитронной эмиссионной компьютерной томографии (ПЭТ) для диагностики, оценки распространенности и мониторинга колоректального рака (КРР).

Материал и методы

Материал и методы. Проведён поиск литературных источников, опубликованных в базах данных Medline, Pubmed и др. по данной проблеме. Было найдено 70 источников, посвященных изучению результатов клинических исследований диагностических возможностей ПЭТ с 18F-фтордезоксиглюкозой (ПЭТ с 18F-ФДГ).

Результаты

Результаты. Представлены данные о возможности ПЭТ с 18F-ФДГ в визуализации первичного опухолевого очага, диагностике лимфогенных и отдаленных метастазов, при оценке эффективности противоопухолевого лечения при КРР.

Заключение

Заключение. Данный обзор литературы показал, что 18F-ФДГ ПЭТ является перспективным методом обследования пациентов с КРР и может быть рекомендован в качестве дополнительного исследования в тех случаях, когда другие методы лучевой диагностики не дают однозначного ответа. Кроме того, 18F-ФДГ ПЭТ является наиболее чувствительным методом в выявлении метастазов КРР в печень, дающим возможность оценивать эффективность терапевтических и хирургических вмешательств, а также прогнозировать течение опухолевого процесса на ранних сроках после начала лечения. Актуальной остается разработка новых РФП, которые позволят повысить доступность использования методов ядерной медицины для диагностики, стадирования, мониторинга и прогноза лечения КРР.

The purpose of the study was to provide up-to-date data on the efficacy of positron emission computed tomography (PET) for the diagnosis, assessment of tumor extension and monitoring of colorectal cancer.

Material and Methods

Material and Methods. The Medline and Pubmed databases were used for searching for publications devoted to clinical trials of diagnostic value of PET with 18F-Ftordesoxyglucose (PET with 18F-FDG).

Results

Results. Data on the value of PET with 18F-FDG in visualization of the primary tumor, detection of lymph node and distant metastases and assessment of the treatment response in patients with colorectal cancer were presented.

Conclusion

Conclusion. PET with 18F-FDG was shown to be a promising imaging method for colorectal cancer. It is the most sensitive method in the detection of liver metastases. 18F-FDG PET is particularly superior to CT and MET in the ability to assess tumor response to treatment and predict early tumor response to therapy. The development of new radiopharmaceuticals for the diagnosis, staging, monitoring and prediction of colorectal cancer is of great importance. 

колоректальный ракпозитронная эмиссионная компьютерная томография18F-фтордезоксиглюкоза99mTc-1-тио-D-глюкозапервичная диагностикаметастазирование в печеньхимиотерапиялучевая терапияcolorectal cancerpositron emission computed tomography18F-Ftordesoxyglucose99mTc-1-thio-D-glucoseprimary diagnosisliver metastasischemotherapyradiation therapyReferencesAmerican Cancer Society. Cancer facts and figures. Atlanta, Georgia, 2008. 72.Guillem J.G., Moore H.G., Akhurst T., Klimstra D., Ruo L., Mazumdar M., Minsky B., Saltz L., Wong W., Larson S. Sequential preoperative fluorodeoxyglucoise-Positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1–7. DOI: 10.1016/j. jamcollsurg.2004.02.024.Алиев В.А., Артамонова Е.В., Барсуков Ю.А., Глебовская В.В., Гордеев С.С., Карачун А.М., Личиницер М.Р., Расулов А.О., Сагайдак И.В., Сидоров Д.В., Ткачев С.И., Трякин А.А., Федянин М.Ю., Шелыгин Ю.А. Клинические рекомендации по диагностике и лечению больных раком прямой кишки. М., 2014. 15.Guillem J.G., Puig-La Calle J.Jr., Akhurst T., Tickoo S., Ruo L., Minsky B.D., Gollub M.J., Klimstra D.S., Mazumdar M., Paty P.B., Macapinlac H., Yeung H., Saltz L., Finn R.D., Erdi Y., Humm J., Cohen A.M., Larson S. Colorectal Cancer 291 Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18- Fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan; 43(1): 18–24.Портной Л.М., Вятчанин О.В. Лучевая диагностика опухолей четырех локализаций (легкого, молочной железы, желудка, толстой кишки) с организационно-методических позиций практического здравоохранения Российской Федерации. Вестник рентгенологии и радиологии. 2005; 4: 4–20.Huebner R.H., Park K.C., Shepherd J.E., Schwimmer J., Czernin J., Phelps M.E., Gambhir S.S. A metaanalysis of the literature for wholebody FDG PET detection of colorectal cancer. J Nucl Med. 2000; 41: 1177–1189.Kluetz P.G., Meltzer C.C., Villemagne V.L., Kinahan P.E., Chander S., Martinelli M.A., Townsend D.W. Combined PET-CT imaging in oncology: Impact on patient management. Clin Positron Imaging. 2000; 3(6): 223–230.American Cancer Society. Cancer facts and figures. Atlanta, Georgia, 2008. 72.Усова А.В., Фролова И.Г., Афанасьев С.Г., Тарасова А.С. Возможности МРТ в диагностике и оценке эффективности лечения рака прямой кишки. Сибирский онкологический журнал. 2012; 5: 74–80.Maas M., Nelemans P.J., Valentini V., Das P., Rödel C., Kuo L.J., Calvo F.A., García-Aguilar J., Glynne-Jones R., Haustermans K., Mohiuddin M., Pucciarelli S., Small W.Jr., Suárez J., Theodoropoulos G., Biondo S., Beets-Tan R.G., Beets G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep; 11(9): 835–44. doi: 10.1016/S1470-2045(10)70172-8.Meta J., Seltzer M., Schiepers C., Silverman D.H., Ariannejad M., Gambhir S.S., Phelps M.E., Valk P., Czernin J. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med. 2001 Apr; 42(4): 586–90.Aliev V.A., Artamonov E.V., Barsukov Yu.A., Glebovskaya V.V., Gordeev S.S., Karachun A.M., Lichinitser M.R., Rasulov A.O., Sagaydak I.V., Sidorov D.V., Tkachev S.I., Tryakin A.A., Fedyanin M.Yu., Shelygin Yu.A. Clinical guidelines for the diagnosis and treatment of patients with rectal cancer. Moscow, 2014. 15. (in Russian).Ruhlmann J., Oehr P., Biersack H.J. PET in Oncology. Berlin; Heidelberg: Springer-Verlag, 2003. 11.Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., Phelps M.E. A tabulated review of the literature. J Nucl Med. 2001; 42 (suppl): 9S–12S.Delbeke D. Oncological application of FDG imaging. J Nucl. Med. 1999; 40(7): 1706–1716.Guillem J.G., Moore H.G., Akhurst T., Klimstra D., Ruo L., Mazumdar M., Minsky B., Saltz L., Wong W., Larson S. Sequential preoperative fluorodeoxyglucoise-Positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1–7. DOI: 10.1016/j. jamcollsurg.2004.02.024.Goldberg H.I., Margulis A.R. Gastrointestinal radiology in the United States: an overview of the past 50 years. Radiology. 2000; 216(1): 1–7. doi: 10.1148/radiology.216.1.r00jl311.Maffione A.M., Chondrogiannis S., Capirci C., Galeotti F., Fornasiero A., Crepaldi G., Grassetto G., Rampin L., Marzola M.C., Rubello D. Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014 Oct; 40(10): 1186–94. doi: 10.1016/j.ejso.2014.06.005.Kinkel K., Lu Y., Both M., Warren R.S., Thoeni R.F. Detection of hepatic metastases from cancer of the gastrointestinal tract by using non invasive imaging methods (US, CT, MRI imaging, PET): a meta-analysis. Ibid. 2002; 224(6): 748–756.Tailor L.M., Vyatchanin O.V. Radiological diagnostics of tumors of four localizations (lung, breast, stomach, colon) from the organizational and methodological positions of practical health care in the Russian Federation. Journal of radiology and nuclear medicine. 2005; 4: 4–20. (in Russian).Stokkel M.P., Draisma A., Pauwels E.K. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol. 2001 May; 127(5): 278–85.Maas M., Nelemans P.J., Valentini V., Das P., Rödel C., Kuo L.J., Calvo F.A., García-Aguilar J., Glynne-Jones R., Haustermans K., Mohiuddin M., Pucciarelli S., Small W.Jr., Suárez J., Theodoropoulos G., Biondo S., Beets-Tan R.G., Beets G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep; 11(9): 835–44. doi: 10.1016/S1470-2045(10)70172-8.Osman M.M., Cohade C., Nakamoto Y., Marshall L.T., Leal J.P., Wahl R.L. Clinically signifi cant inaccurate localization of lesions with PET/ CT: frequency in 300 patients. J Nucl Med. 2003 Feb; 44(2): 240–3.Meta J., Seltzer M., Schiepers C., Silverman D.H., Ariannejad M., Gambhir S.S., Phelps M.E., Valk P., Czernin J. Impact of 18F-FDG PET on Managing Patients with Colorectal Cancer: The Referring Physician’s Perspective. J Nucl Med. 2001 Apr; 42(4): 586–90.Coleman R.E. Clinical PET in oncology. Clin. Posi. Imaging. 1998; 1(2): 15–30. doi: 10.1016/S1095-0397(97)00004-6.Anderson C., Koshy M., Staley C., Esiashvili N., Ghavidel S., Fowler Z., Fox T., Esteves F., Landry J., Godette K. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007 Sep 1; 69(1): 155–62. doi: 10.1016/j.ijrobp.2007.02.055.Wahl R.L., Quint L.E., Cieslak R.D., Aisen A.M., Koeppe R.A., Meyer C.R. Anatometabolic tumor imaging: fusion of FDG PET with CT and MRI to localize foci of increased activity. J Nucl Med. 1993 Jul; 34(7): 1190–7.Patel D.A., Chang S.T., Goodman K.A., Quon A., Thorndyke B., Gambhir S.S., McMillan A., Loo B.W.Jr., Koong A.C. Impact of integrated PET/ CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007 Feb; 6(1): 31–6. doi: 10.1177/153303460700600105.Kostenikov N.A., Ryzhkova D.V., Stanzhevsky A.A., Tlostanova M.S., Balabanova A., Plotkin M., Sukhov V., Zaplatnikov K. Positron emission tomography. Springer-Verlag Berlin, 2013. doi: 10.1007/978-3-642-21120-1.Moore H.G., Akhurst T., Larson S.M., Minsky B.D., Mazumdar M., Guillem J.G. A case controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003; 197: 22–28. doi: 10.1016/S1072-7515(03)00337-5.Gontier E., Fourme E., Wartski M., Blondet C., Bonardel G., Le Stanc E., Mantzarides M., Foehrenbach H., Pecking A.P., Alberini J.L. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1): 95–9.Guillem J.G., Puig-La Calle J.Jr., Akhurst T., Tickoo S., Ruo L., Minsky B.D., Gollub M.J., Klimstra D.S., Mazumdar M., Paty P.B., Macapinlac H., Yeung H., Saltz L., Finn R.D., Erdi Y., Humm J., Cohen A.M., Larson S. Colorectal Cancer 291 Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18- Fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan; 43(1): 18–24.Gauthé M., Richard-Molard M., Cacheux W., Michel P., Jouve J.L., Mitry E., Alberini J.L., Lièvre A.; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis. 2015 Jun; 47(6): 443–54. doi: 10.1016/j.dld.2015.02.005.Guillem J.G., Moore H.G., Akhurst T., Klimstra D., Ruo L., Mazumdar M., Minsky B., Saltz L., Wong W., Larson S. Sequential preoperative fluorodeoxyglucoise-Positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1–7. DOI: 10.1016/j. jamcollsurg.2004.02.024.Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011 Nov 24; 9: 154. doi: 10.1186/1477-7819-9-154.Maas M., Nelemans P.J., Valentini V., Das P., Rödel C., Kuo L.J., Calvo F.A., García-Aguilar J., Glynne-Jones R., Haustermans K., Mohiuddin M., Pucciarelli S., Small W.Jr., Suárez J., Theodoropoulos G., Biondo S., Beets-Tan R.G., Beets G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep; 11(9): 835–44. doi: 10.1016/S1470-2045(10)70172-8.Maffione A.M., Lopci E., Bluemel C., Giammarile F., Herrmann K., Rubello D. Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015 Jan; 42(1): 152–63. doi: 10.1007/s00259-014-2930-4.Maffione A.M., Chondrogiannis S., Capirci C., Galeotti F., Fornasiero A., Crepaldi G., Grassetto G., Rampin L., Marzola M.C., Rubello D. Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014 Oct; 40(10): 1186–94. doi: 10.1016/j.ejso.2014.06.005.Bar-Shalom R., Yefremov N., Guralnik L., Gaitini D., Frenkel A., Kuten A., Altman H., Keidar Z., Israel O. Clinical performance of PET/CT in the evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med. 2003 Aug; 44(8): 1200–9. 21. Roman C.D., Martin W.H., Delbeke D. Incremental value of fusion imaging with integrated PET-CT in oncology. Clin Nucl Med 2005; 30: 470–477.Maffione A.M., Marzola M.C., Capirci C., Colletti P.M., Rubello D. Value of 18F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. Am J Roentgenol. 2015 Jun; 204(6): 1261–8. doi: 10.2214/AJR.14.13210.Cohade C., Osman M., Leal J., Wahl R.L. Direct comparison of FDG PET and PET-CT imaging in colorectal carcinoma. J Nucl Med. 2003 Nov; 44(11): 1797–803.Fendler W.P., Philippe Tiega D.B., Ilhan H., Paprottka P.M., Heinemann V., Jakobs T.F., Bartenstein P., Hacker M., Haug A.R. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013 Aug; 54(8): 1202–8. doi: 10.2967/jnumed.112.116426.Selzner M., Hany T.F., Wildbrett P., McCormack L., Kadry Z., Clavien P.A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004 Dec; 240(6): 1027–34.Guillem J.G., Ruby J.A., Leibold T., Akhurst T.J., Yeung H.W., Gollub M.J., Ginsberg M.S., Shia J., Suriawinata A.A., Riedel E.R., Mazumdar M., Saltz L.B., Minsky B.D., Nash G.M., Paty P.B., Temple L.K., Weiser M.R., Larson S.M. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013 Aug; 258(2): 289–95. doi: 10.1097/ SLA.0b013e318277b625.Soyka J.D., Veit-Haibach P., Strobel K., Breitenstein S., Tschopp A., Mende K.A., Perez Lago M., Hany T.F. Staging pathways in recurrent colorectal carcinoma: Is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice? J Nucl Med. 2008 Mar; 49(3): 354–61. doi: 10.2967/jnumed.107.048249.Maas M., Rutten I.J., Nelemans P.J., Lambregts D.M., Cappendijk V.C., Beets G.L., Beets-Tan R.G. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011 Aug; 38(8): 1560–71. doi: 10.1007/ s00259-011-1785-1.Tateishi U., Maeda T., Morimoto T., Miyake M., Arai Y., Kim E.E. Non-enhanced CT versus contrastenhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007; 34: 1627–1634.Lu Y.Y., Chen J.H., Chien C.R., Chen W.T.L., Tsai S.C., Lin W.Y., Kao C.H. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis, 2013; 28: 1039–1047.Huebner R.H., Park K.C., Shepherd J.E., Schwimmer J., Czernin J., Phelps M.E., Gambhir S.S. A metaanalysis of the literature for wholebody FDG PET detection of colorectal cancer. J Nucl Med. 2000; 41: 1177–1189.Sanli Y., Kuyumcu S., Ozkan Z.G., Kilic L., Balik E., Turkmen C., Has D., Isik G., Asoglu O., Kapran Y., Adalet I. The utility of FDG-PET/ CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012 Aug; 26(7): 551–8. doi: 10.1007/s12149-012-0609-0.Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., Phelps M.E. A tabulated review of the literature. J Nucl Med. 2001; 42 (suppl): 9S–12S.Even-Sapir E., Parag Y., Lerman H., Gutman M., Levine C., Rabau M., Metser U. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232: 815–822.Meta J., Seltzer M., Schiepers C., Silverman D.H., Ariannejad M., Gambhir S.S., Phelps M.E., Valk P., Czernin J. Impact of 18F-FDG PET on Managing Patients with Colorectal Cancer: The Referring Physician’s Perspective. J Nucl Med. 2001 Apr; 42(4): 586–90.Langenhoff B.S., Oyen W.J., Jager G.J., Strijk S.P., Wobbes T., Corstens F.H., Ruers T.J. Efficacy of fluorine18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002 Nov 15; 20(22): 4453–8. doi: 10.1200/JCO.2002.12.134.Ruers T.J., Langenhoff B.S., Neeleman N., Jager G.J., Strijk S., Wobbes T., Corstens F.H.M., Oyen W.J.G. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002; 20: 388–395.Afanasyev S.G., Tuzikov S.A. Inoperable liver tumors (literature review). Siberian Journal of Oncology. 2006; 1: 49–54. (in Russian).Wiering B., Krabbe P.F., Jager G.J., Oyen W.J., Ruers T.J. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 15(104): 2658–2670.Lin M., Shon I.H., Wilson R., D’Amours S.K., Schlaphoff G., Lin P. Treatment response in liver metastases following 90Y SIR-spheres: An evaluation with PET. Hepatogastroenterology. 2007 Apr-May; 54(75): 910–2.Scott A.M., Gunawardana D.H., Kelley B., Stuckey J.G., Byrne A.J., Ramshaw J.E., Fulham M.J. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: Results of a multicenter prospective study. J Nucl Med. 2008 Sep; 49(9): 1451–7. doi: 10.2967/jnumed.108.051615.Wong C.Y., Salem R., Raman S., Gates V.L., Dworkin H.J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002 Jun; 29(6): 815–20. doi: 10.1007/s00259- 002-0787-4.Strasberg S.M., Dehdashti F., Siegel B.A., Drebin J.A., Linehan D. Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg 2001; 233: 320–321. doi: 10.1097/00000658-200103000-00001.Chernov V.I., Medvedev A.A., Sinilkin I.G., Zelchan R.V., Bragina O.D., Choynzonov E.L. Nuclear medicine as a tool for diagnosis and targeted cancer therapy. Bulletin of Siberian Medicine. 2018; 1(17): 220–231. (in Russian).Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438–447; discussion 447–450. doi: 10.1097/01.sla.0000138076.72547.b1.Zeltchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.V., Chernov V.J. Radiopharmaceuticals based on the glucose derivatives for tumor diagnosis. Siberian Journal of Oncology. 2018; 17(2): 71–81. (in Russian). doi: 10.21294/1814-4861-2018-17-2-71-81.Wiering B., Krabbe P.F., Dekker H.M., Oyen W.J., Ruers T.J. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007; 14: 771–779. doi: 10.1245/s10434-006-9013-0.Chernov V.I., Dudnikova E.A., Goldberg V.E., Kravchuk T.L., Danilova A.V., Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Popova N.O., Goldberg A.V. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. 2018; 6(63): 41–50. (in Russian).Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005; 10: 250–261. doi: 10.1634/theoncologist.10-4-250.Stasyuk E.S., Skuridin V.S., Ilina E.A., Rogov A.S., Nesterov E.A., Sadkin V.L., Larionova L.A., Varlamova N.V., Zelchan R.V. Development new radiopharmaceutical based on 5-thio-D-glucose labeled technetium99m. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine», 2016. 012044.Findlay M., Young H., Cunningham D., Iveson A., Cronin B., Hickish T., Pratt B., Husband J., Flower M., Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol. 1996; 14: 700–8. doi: 10.1200/JCO.1996.14.3.700.Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zelchan R.V., Bragina O.D., Skuridin V.S. Experience in developing innovative radiopharmaceuticals at the Tomsk Oncology Research Institute. Siberian Journal of Oncology. 2015; S2: 45–47. (in Russian).Akhurst T., Kates T.J., Mazumdar M., Yeung H., Riedel E.R., Burt B.M., Blumgart L., Jarnagin W., Larson S.M., Fong Y. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005 Dec 1; 23(34): 8713–6. doi: 10.1200/JCO.2005.04.4222Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zeltchan R.V., Bragina O.D. Development Radiopharmaceuticals for Nuclear Medicine in Oncology. Medical Visualization. 2016; 2: 63–66. (in Russian).Takahashi S., Kuroki Y., Nasu K., Nawano S., Konishi M., Nakagohri T., Gotohda N., Saito N., Kinoshita T. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res. 2006 Nov-Dec; 26(6C): 4705–11.Zelchan R.V., Medvedeva A.A., Bragina O.D., Sinilkin I.G., Chernov V.I., Stasyuk E.S., Tagirova E.A., Skuridin V.S. The study of the acute toxicity of new radiopharmaceuticals 99mTc-1-thio-D-glucose in the experiment. Molecular medicine. 2019; 1(17): 58–64. (in Russian).Carnaghi C., Tronconi M.C., Rimassa L., Tondulli L., Zuradelli M., Rodari M., Doci R., Luttmann F., Torzilli G., Rubello D., Al-Nahhas A., Santoro A., Chiti A. Utility of 18F-FDG PET and contrastenhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur. 2007; 10(1): 12–5.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Stasyuk E., Rogov A., Skuridin V. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose. AIP Publishing, 2016; 1760(1).Lubezky N., Metser U., Geva R., Nakache R., Shmueli E., Klausner J.M., Even-Sapir E., Figer A., BenHaim M. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings. J Gastrointest Surg. 2007 Apr; 11(4): 472–8. doi: 10.1007/s11605-006-0032-8.Zeltchan R., Medvedeva A., Sinilkin I., Bragina O., Chernov V., Stasyuk E., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering. 2016; 012054.Tan M.C., Linehan D.C., Hawkins W.G., Siegel B.A., Strasberg S.M. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007 Sep; 11(9): 1112–9. doi: 10.1007/s11605-007-0218-8.Zeltchan R., Medvedeva A., Sinilkin I., Bragina O., Chernov V., Stasyuk E., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering. 2016; 012054.Афанасьев С.Г., Старцева Ж.А., Тарасова А.С., Усова А.В., Самцов Е.Н. Результаты комбинированного лечения рака прямой кишки с применением пролонгированной предоперационной химиолучевой терапии. Сибирский онкологический журнал. 2012; 6: 5–12.Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina OD, Chernov V.I., Stasyuk E.S., Ilina E.A., Skuridin V.S. The study of the functional suitability of the tumororotropic radiopharmaceutical 99mTc-1-TIO-6-glucose in the experiment. Molecular medicine. 2018; 3 (16): 54–57. (in Russian).Anderson C., Koshy M., Staley C., Esiashvili N., Ghavidel S., Fowler Z., Fox T., Esteves F., Landry J., Godette K. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007 Sep 1; 69(1): 155–62. doi: 10.1016/j.ijrobp.2007.02.055.Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina OD, Chernov V.I., Stasyuk E.S., Ilina E.A., Skuridin V.S. The study of the functional suitability of the tumororotropic radiopharmaceutical 99mTc-1-TIO-6-glucose in the experiment. Molecular medicine. 2018; 3 (16): 54–57. (in Russian).Patel D.A., Chang S.T., Goodman K.A., Quon A., Thorndyke B., Gambhir S.S., McMillan A., Loo B.W.Jr., Koong A.C. Impact of integrated PET/ CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007 Feb; 6(1): 31–6. doi: 10.1177/153303460700600105.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il'Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine». 2016. 012054.Moore H.G., Akhurst T., Larson S.M., Minsky B.D., Mazumdar M., Guillem J.G. A case controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003; 197: 22–28. doi: 10.1016/S1072-7515(03)00337-5.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il'Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine». 2016. 012054.Guillem J.G., Puig-La Calle J.Jr., Akhurst T., Tickoo S., Ruo L., Minsky B.D., Gollub M.J., Klimstra D.S., Mazumdar M., Paty P.B., Macapinlac H., Yeung H., Saltz L., Finn R.D., Erdi Y., Humm J., Cohen A.M., Larson S. Colorectal Cancer 291 Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18- Fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan; 43(1): 18–24.Chernov V.I., Dudnikova E.A., Zelchan R.V., Kravchuk T.L., Danilova A.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Goldberg V.E., Goldberg A.V., Frolova I.G. The first experience of using 99mtc-1-thio-d-glucose for single-photon emission computed tomography imaging of lymphomas. Siberian Journal of Oncology. 2018; 17(4): 81–87. (in Russian). Doi: 10.21294/1814-4861-2018-17-4-81-87.Guillem J.G., Moore H.G., Akhurst T., Klimstra D., Ruo L., Mazumdar M., Minsky B., Saltz L., Wong W., Larson S. Sequential preoperative fluorodeoxyglucoise-Positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1–7. DOI: 10.1016/j. jamcollsurg.2004.02.024.Chernov V.I., Dudnikova E.A., Zelchan R.V., Kravchuk T.L., Danilova A.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Goldberg V.E., Goldberg A.V., Frolova I.G. The first experience of using 99mtc-1-thio-d-glucose for single-photon emission computed tomography imaging of lymphomas. Siberian Journal of Oncology. 2018; 17(4): 81–87. (in Russian). Doi: 10.21294/1814-4861-2018-17-4-81-87.Maas M., Nelemans P.J., Valentini V., Das P., Rödel C., Kuo L.J., Calvo F.A., García-Aguilar J., Glynne-Jones R., Haustermans K., Mohiuddin M., Pucciarelli S., Small W.Jr., Suárez J., Theodoropoulos G., Biondo S., Beets-Tan R.G., Beets G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep; 11(9): 835–44. doi: 10.1016/S1470-2045(10)70172-8.Maas M., Nelemans P.J., Valentini V., Das P., Rödel C., Kuo L.J., Calvo F.A., García-Aguilar J., Glynne-Jones R., Haustermans K., Mohiuddin M., Pucciarelli S., Small W.Jr., Suárez J., Theodoropoulos G., Biondo S., Beets-Tan R.G., Beets G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep; 11(9): 835–44. doi: 10.1016/S1470-2045(10)70172-8.Maffione A.M., Chondrogiannis S., Capirci C., Galeotti F., Fornasiero A., Crepaldi G., Grassetto G., Rampin L., Marzola M.C., Rubello D. Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014 Oct; 40(10): 1186–94. doi: 10.1016/j.ejso.2014.06.005.Maffione A.M., Chondrogiannis S., Capirci C., Galeotti F., Fornasiero A., Crepaldi G., Grassetto G., Rampin L., Marzola M.C., Rubello D. Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014 Oct; 40(10): 1186–94. doi: 10.1016/j.ejso.2014.06.005.Maffione A.M., Marzola M.C., Capirci C., Colletti P.M., Rubello D. Value of 18F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. Am J Roentgenol. 2015 Jun; 204(6): 1261–8. doi: 10.2214/AJR.14.13210.Maffione A.M., Marzola M.C., Capirci C., Colletti P.M., Rubello D. Value of 18F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. Am J Roentgenol. 2015 Jun; 204(6): 1261–8. doi: 10.2214/AJR.14.13210.Fendler W.P., Philippe Tiega D.B., Ilhan H., Paprottka P.M., Heinemann V., Jakobs T.F., Bartenstein P., Hacker M., Haug A.R. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013 Aug; 54(8): 1202–8. doi: 10.2967/jnumed.112.116426.Fendler W.P., Philippe Tiega D.B., Ilhan H., Paprottka P.M., Heinemann V., Jakobs T.F., Bartenstein P., Hacker M., Haug A.R. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013 Aug; 54(8): 1202–8. doi: 10.2967/jnumed.112.116426.Guillem J.G., Ruby J.A., Leibold T., Akhurst T.J., Yeung H.W., Gollub M.J., Ginsberg M.S., Shia J., Suriawinata A.A., Riedel E.R., Mazumdar M., Saltz L.B., Minsky B.D., Nash G.M., Paty P.B., Temple L.K., Weiser M.R., Larson S.M. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013 Aug; 258(2): 289–95. doi: 10.1097/ SLA.0b013e318277b625.Guillem J.G., Ruby J.A., Leibold T., Akhurst T.J., Yeung H.W., Gollub M.J., Ginsberg M.S., Shia J., Suriawinata A.A., Riedel E.R., Mazumdar M., Saltz L.B., Minsky B.D., Nash G.M., Paty P.B., Temple L.K., Weiser M.R., Larson S.M. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013 Aug; 258(2): 289–95. doi: 10.1097/ SLA.0b013e318277b625.Maas M., Rutten I.J., Nelemans P.J., Lambregts D.M., Cappendijk V.C., Beets G.L., Beets-Tan R.G. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011 Aug; 38(8): 1560–71. doi: 10.1007/ s00259-011-1785-1.Maas M., Rutten I.J., Nelemans P.J., Lambregts D.M., Cappendijk V.C., Beets G.L., Beets-Tan R.G. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011 Aug; 38(8): 1560–71. doi: 10.1007/ s00259-011-1785-1.Lu Y.Y., Chen J.H., Chien C.R., Chen W.T.L., Tsai S.C., Lin W.Y., Kao C.H. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis, 2013; 28: 1039–1047.Lu Y.Y., Chen J.H., Chien C.R., Chen W.T.L., Tsai S.C., Lin W.Y., Kao C.H. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis, 2013; 28: 1039–1047.Sanli Y., Kuyumcu S., Ozkan Z.G., Kilic L., Balik E., Turkmen C., Has D., Isik G., Asoglu O., Kapran Y., Adalet I. The utility of FDG-PET/ CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012 Aug; 26(7): 551–8. doi: 10.1007/s12149-012-0609-0.Sanli Y., Kuyumcu S., Ozkan Z.G., Kilic L., Balik E., Turkmen C., Has D., Isik G., Asoglu O., Kapran Y., Adalet I. The utility of FDG-PET/ CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012 Aug; 26(7): 551–8. doi: 10.1007/s12149-012-0609-0.Even-Sapir E., Parag Y., Lerman H., Gutman M., Levine C., Rabau M., Metser U. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232: 815–822.Even-Sapir E., Parag Y., Lerman H., Gutman M., Levine C., Rabau M., Metser U. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232: 815–822.Langenhoff B.S., Oyen W.J., Jager G.J., Strijk S.P., Wobbes T., Corstens F.H., Ruers T.J. Efficacy of fluorine18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002 Nov 15; 20(22): 4453–8. doi: 10.1200/JCO.2002.12.134.Langenhoff B.S., Oyen W.J., Jager G.J., Strijk S.P., Wobbes T., Corstens F.H., Ruers T.J. Efficacy of fluorine18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002 Nov 15; 20(22): 4453–8. doi: 10.1200/JCO.2002.12.134.Афанасьев С.Г., Тузиков С.А. Нерезектабельные опухоли печени (обзор литературы). Сибирский онкологический журнал. 2006; 1: 49–54. [Afanasyev S.G., Tuzikov S.A. Inoperable liver tumors (literature review). Siberian Journal of Oncology. 2006; 1: 49–54. (in Russian)].Афанасьев С.Г., Тузиков С.А. Нерезектабельные опухоли печени (обзор литературы). Сибирский онкологический журнал. 2006; 1: 49–54. [Afanasyev S.G., Tuzikov S.A. Inoperable liver tumors (literature review). Siberian Journal of Oncology. 2006; 1: 49–54. (in Russian)].Lin M., Shon I.H., Wilson R., D’Amours S.K., Schlaphoff G., Lin P. Treatment response in liver metastases following 90Y SIR-spheres: An evaluation with PET. Hepatogastroenterology. 2007 Apr-May; 54(75): 910–2.Lin M., Shon I.H., Wilson R., D’Amours S.K., Schlaphoff G., Lin P. Treatment response in liver metastases following 90Y SIR-spheres: An evaluation with PET. Hepatogastroenterology. 2007 Apr-May; 54(75): 910–2.Wong C.Y., Salem R., Raman S., Gates V.L., Dworkin H.J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002 Jun; 29(6): 815–20. doi: 10.1007/s00259- 002-0787-4.Wong C.Y., Salem R., Raman S., Gates V.L., Dworkin H.J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002 Jun; 29(6): 815–20. doi: 10.1007/s00259- 002-0787-4.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Чойнзонов Е.Л. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2018; 1(17): 220–231.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Чойнзонов Е.Л. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2018; 1(17): 220–231.Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И. Диагностические радиофармацевтические препараты на основе производных глюкозы в современной онкологической практике. Сибирский онкологический журнал. 2018; 2(17): 71–81. doi: 10.21294/1814-4861-2018-17-2-71-81.Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И. Диагностические радиофармацевтические препараты на основе производных глюкозы в современной онкологической практике. Сибирский онкологический журнал. 2018; 2(17): 71–81. doi: 10.21294/1814-4861-2018-17-2-71-81.Чернов В.И., Дудникова Е.А., Гольдберг В.Е., Кравчук Т.Л., Данилова А.В., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Попова Н.О., Гольдберг А.В. Позитронная эмиссионная томография в диагностике и мониторинге лимфопролиферативных заболеваний. Медицинская радиология и радиационная безопасность. 2018; 6(63): 41–50.Чернов В.И., Дудникова Е.А., Гольдберг В.Е., Кравчук Т.Л., Данилова А.В., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Попова Н.О., Гольдберг А.В. Позитронная эмиссионная томография в диагностике и мониторинге лимфопролиферативных заболеваний. Медицинская радиология и радиационная безопасность. 2018; 6(63): 41–50.Stasyuk E.S., Skuridin V.S., Ilina E.A., Rogov A.S., Nesterov E.A., Sadkin V.L., Larionova L.A., Varlamova N.V., Zelchan R.V. Development new radiopharmaceutical based on 5-thio-D-glucose labeled technetium99m. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine», 2016. 012044.Stasyuk E.S., Skuridin V.S., Ilina E.A., Rogov A.S., Nesterov E.A., Sadkin V.L., Larionova L.A., Varlamova N.V., Zelchan R.V. Development new radiopharmaceutical based on 5-thio-D-glucose labeled technetium99m. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine», 2016. 012044.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Скуридин В.С. Опыт разработки инновационных радиофармпрепаратов в Томском НИИ онкологии. Сибирский онкологический журнал. 2015; S2: 45–47.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Скуридин В.С. Опыт разработки инновационных радиофармпрепаратов в Томском НИИ онкологии. Сибирский онкологический журнал. 2015; S2: 45–47.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д. Разработка радиофармпрепаратов для радионуклидной диагностики в онкологии. Медицинская визуализация. 2016; 2: 63–66.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д. Разработка радиофармпрепаратов для радионуклидной диагностики в онкологии. Медицинская визуализация. 2016; 2: 63–66.Зельчан Р.В., Медведева А.А., Брагина О.Д., Синилкин И.Г., Чернов В.И., Стасюк Е.С., Тагирова Е.А., Скуридин В.С. Изучение общей острой токсичности нового радиофармпрепарата 99mTc-1-тио-Dглюкоза в эксперименте. Молекулярная медицина. 2019; 1(17): 58–64.Зельчан Р.В., Медведева А.А., Брагина О.Д., Синилкин И.Г., Чернов В.И., Стасюк Е.С., Тагирова Е.А., Скуридин В.С. Изучение общей острой токсичности нового радиофармпрепарата 99mTc-1-тио-Dглюкоза в эксперименте. Молекулярная медицина. 2019; 1(17): 58–64.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Stasyuk E., Rogov A., Skuridin V. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose. AIP Publishing, 2016; 1760(1).Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Stasyuk E., Rogov A., Skuridin V. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose. AIP Publishing, 2016; 1760(1).Zeltchan R., Medvedeva A., Sinilkin I., Bragina O., Chernov V., Stasyuk E., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering. 2016; 012054.Zeltchan R., Medvedeva A., Sinilkin I., Bragina O., Chernov V., Stasyuk E., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering. 2016; 012054.Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И., Стасюк Е.С., Ильина Е.А., Скуридин В.С. Изучение функциональной пригодности туморотропного радиофармпрепарата 99mTс-1-ТИО-6-глюкоза в эксперименте. Молекулярная медицина. 2018; 3(16): 54–57.Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И., Стасюк Е.С., Ильина Е.А., Скуридин В.С. Изучение функциональной пригодности туморотропного радиофармпрепарата 99mTс-1-ТИО-6-глюкоза в эксперименте. Молекулярная медицина. 2018; 3(16): 54–57.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il'Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine». 2016. 012054.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il'Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering 8. VIII International Scientific Conference «Issues of Physics and Technology in Science, Industry and Medicine». 2016. 012054.Чернов В.И., Дудникова Е.А., Зельчан Р.В., Кравчук Т.Л., Данилова А.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Гольдберг В.Е., Гольдберг А.В., Фролова И.Г. Однофотонная эмиссионная компьютерная томография с 99mtc-1-тио-d-глюкозой в диагностике и стадировании злокачественных лимфом: первый опыт использования. Сибирский онкологический журнал. 2018; 17(4): 81–87. Doi: 10.21294/1814-4861-2018-17-4-81-87.Чернов В.И., Дудникова Е.А., Зельчан Р.В., Кравчук Т.Л., Данилова А.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Гольдберг В.Е., Гольдберг А.В., Фролова И.Г. Однофотонная эмиссионная компьютерная томография с 99mtc-1-тио-d-глюкозой в диагностике и стадировании злокачественных лимфом: первый опыт использования. Сибирский онкологический журнал. 2018; 17(4): 81–87. Doi: 10.21294/1814-4861-2018-17-4-81-87.

The authors declare that there are no conflicts of interest present.